Press release article from our research archive:

Pulmonary Hypertension - New Potential in a Limited Market.

RDATE:07022002

Pulmonary hypertension is a niche market that has, up until recently, been largely neglected in terms of the development of practical treatments.

However, the number of promising compounds now in late stage development, as evidenced by the filing of the first endothelin receptor antagonist, Tracleer (bosentan), in Europe in February 2001, provides an ideal opportunity to assess the future prospects of this market.

This brief discusses some of the major issues within the pulmonary hypertension market and outlines possible future developments.

So, what do you get from this report?

Pulmonary Hypertension - New Potential in a Limited ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!